The field of health care is progressively being entered by artificial intelligence, which is assisting in streamlining medical procedures, including the development of new pharmaceuticals.
A new AI-designed medicine for COVID-19 has started Phase I clinical trials, according to the Hong Kong- and New York City-based biotech business Insilico Medicine.
This medication is used orally and is not a vaccination. According to Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine, if approved, it would be the first-ever Paxlovid substitute.
In a news release reporting the new finding, Zhavoronkov stated that “generative AI is transforming every area of human development.” We are overjoyed to report that the human clinical trials for our second small molecule therapy, which was created using generative AI, have begun.
According to Insilico, there have been some negative side effects associated with paxlovid, which is the only medicine currently on the market for treating COVID-19 symptoms. One of these is “Paxlovid rebound,” in which individuals who have recovered from COVID test negative initially but then test positive again shortly after.
Another known adverse effect is “Paxlovid mouth,” which is when someone taking the medication experiences an unfavorable aftertaste in their tongue. According to Insilico, there have been some negative side effects associated with paxlovid, which is the only medicine currently on the market for treating COVID-19 symptoms.
One of these is “Paxlovid rebound,” in which individuals who have recovered from COVID test negative initially but then test positive again shortly after. Another known adverse effect is “Paxlovid mouth,” which is when someone taking the medication experiences an unfavorable aftertaste in their tongue.
According to Zhavoronkov, the new medication from Insilico has been proven to be effective against Paxlovid-resistant versions and to be more stable and last longer. According to the company’s press announcement, ISM3312 “significantly reduced” viral load in lung tissue and lung inflammation in preclinical testing. The target protein within the coronavirus was initially discovered by Insilico’s research team using its target discovery tool, PandaOmics. It then created new compounds that would target that protein to treat COVID and other coronaviruses using its in-house “generative chemistry platform,” Chemistry42.
ISM3312, a single “hit molecule,” was demonstrated to be efficient in February 2020. In April 2020, the business then submitted a patent application for the medication. According to Zhavoronkov of Fox News Digital, “The medication is effective against all variants as well as other kinds of coronaviruses that cause diseases, including severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS).”
The recently found compound by Insilico has been demonstrated to have “broad antivirus activity against multiple strains and variants,” the researcher stated. According to Zhavoronkov, another advantage of the new medicine is that it will be simple to manufacture in large amounts. Our molecule just needs a two-step procedure employing basic, readily available starting components, the scientist claimed. Phase 1 research is now being conducted on ISM3312 to examine the medication’s safety and tolerability in healthy volunteers. Additionally, the drug is presently being examined against the EG.5 COVID variant.
By the end of 2023, the clinical study results are anticipated to be made public. Further considerations regarding testing the substance on coronavirus-infected patients will be made after the Phase 1 healthy volunteer trial is finished, according to Zhavoronkov.
